Phibro Animal Health has delivered a very strong share price return over the past few years, even as the stock has recently pulled back. With that kind of history on the chart, the key issue for you now is whether the current price can be explained by the earnings the business is generating. Over the last 3 years, Phibro Animal Health has gained about 2.6x. That puts a lot of weight on whether its profit power really supports that move. Recent reports show higher revenue and reaffirmed...
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Phibro Animal Health has seen its share price move around in recent years, and that raises a straightforward question for investors who focus on fundamentals. Is the current US$38.80 price tag adequately supported by the earnings the company is generating today? Over the past 3 years the stock has delivered a very large gain of 284.1%, which puts real pressure on the question of whether current earnings can carry that kind of re-rating. The business model is tied closely to recurring demand...
Phibro (PAHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Phibro Animal Health (PAHC) has come into focus after recent share price moves. The stock closed at US$37.40 on 9 October 2026 and has shown mixed short and longer term returns. Recent trading has been choppy for Phibro Animal Health, with the share price slipping 0.9% on the day but still posting a 16.6% 90 day share price return and a very large 3 year total shareholder return. This hints at shifting expectations around its growth prospects and risk profile rather than a simple short term...
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Shareholders of Phibro Animal Health would probably like to forget the past six months even happened. The stock dropped 38.5% and now trades at $34.11. This may have investors wondering how to approach the situation.
TEANECK, N.J., September 09, 2026--Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Morgan Stanley Annual Global Healthcare Conference.
Phibro Animal Health earnings and guidance set the tone Phibro Animal Health (PAHC) drew investor attention after issuing earnings guidance for the fiscal year ending June 30, 2027, alongside reporting fourth quarter and full year 2026 results. The company now projects 2027 net sales of US$1.55b to US$1.60b and net income of US$122 million to US$132 million. Expected diluted EPS is US$2.98 to US$3.22. These figures follow 2026 sales of US$1,518.09 million and net income of US$99.72...
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
PAHC’s Zoetis MFA acquisition boosts animal-health growth via vaccines and companion animals. Click for more on PAHC stock.
Phibro Animal Health (NASDAQ:PAHC) reported record fiscal 2026 sales and a sharp increase in adjusted EBITDA, supported by growth in its Animal Health and Mineral Nutrition businesses, the integration of its acquired Zoetis medicated feed additive portfolio, and operational initiatives under its Phi
Motley Fool Press Release.
Moby summary of Phibro Animal Health Corporation's Q4 2026 earnings call
Phibro Animal Health Corp (PAHC) posts record FY2026 results with 39% adjusted EBITDA growth, while navigating Brazil regulatory uncertainty and executing strategic manufacturing optimization.
Detailed price information for Phibro Anl Htlh A (PAHC-Q) from The Globe and Mail including charting and trades.
Phibro (PAHC) delivered earnings and revenue surprises of +18.06% and +8.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Animal health products manufacturer Phibro Animal Health (NASDAQ:PAHC) announced better-than-expected revenue in Q2 CY2026, with sales up 4.8% year on year to $396.7 million. The company’s full-year revenue guidance of $1.58 billion at the midpoint came in 1.9% above analysts’ estimates. Its non-GAAP profit of $0.85 per share was 17.1% above analysts’ consensus estimates.
TEANECK, N.J., August 26, 2026--Phibro Animal Health Corporation (Nasdaq: PAHC) ("Phibro" or the "Company") today announced financial results for its fourth quarter and fiscal year ended June 30, 2026 and provided its financial guidance for the fiscal year ending June 30, 2027.
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
Although the revenue and EPS for Phibro (PAHC) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Phibro Animal Health (PAHC) reported fiscal Q4 adjusted earnings late Wednesday of $0.85 per diluted
Animal health products manufacturer Phibro Animal Health (NASDAQ:PAHC) will be reporting earnings this Wednesday afternoon. Here’s what investors should know.
Besides Wall Street's top-and-bottom-line estimates for Phibro (PAHC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.
This is the newest page. Registered accounts read further back.